Adenovirus-mediated lymphotactin gene transfer improves therapeutic efficacy of cytosine deaminase suicide gene therapy in established murine colon carcinoma

Gene Therapy

Volumn 7, Issue 4, 2000, Pages 329-338

  Ju, D W ^a   Tao, Q ^a   Cheng, D S ^a   Zhang, W ^a   Zhang, M ^a   Hamada, H ^b   Cao, X ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b Foundation for the Promotion of Cancer Research (Japan)   (Japan)

Author keywords

Adenovirus; Antitumor immunity; Cytosine deaminase; Gene therapy; Lymphotactin

Indexed keywords

B7 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; CYTOSINE DEAMINASE; FAS ANTIGEN; FLUCYTOSINE; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2; LYMPHOTACTIN; MESSENGER RNA;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL INFILTRATION; COLON CARCINOMA; FEMALE; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; IMMUNE RESPONSE; LYMPHOCYTE; MALE; MESSENGER RNA SYNTHESIS; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SUICIDE GENE; T LYMPHOCYTE;

ADENOVIRIDAE; ANIMALIA; MURINAE;

EID: 0033995097     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301082     Document Type: Article

References (47)

1. Mullen CA. Metabolic suicide genes in gene therapy. Pharm Ther 1994; 63: 199-207.
2. Tiberghien P. Use of suicide genes in gene therapy. J Leuk Biol 1994; 56: 203-209.
3. Deonarain MP, Spooner RA, Epenetos AA. Genetic delivery of enzymes for cancer therapy. Gene Therapy 1995; 2: 235-244.
4. Dilber MS et al. Suicide gene therapy for plasma cell tumors. Blood 1996; 88: 2192-2200.
5. Cryslal RG et al. Phase I study of direct administration of a replication deficient adenovirus vector containing the E. coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine. Hum Gene Ther 1997; 8: 985-1001.
6. Done, Y et al. In vivo replication-deficient adenovirus vector-mediated transduction of the cytosine deaminase gene sensitizes glioma cells to 5-fluorocytosine. Hum Gene Ther 1996; 7: 713-720.
7. Li Z et al. Enzyme/prodrug gene therapy approach for breast cancer using a recombinant adenovirus expressing Escherichia coli cytosine deaminase. Cancer Gene Ther 1997; 4: 113-117.
8. Topf N, Worgall S, Hackett NR, Crystal RG. Regional 'pro-drug' gene therapy: intravenous administration of an adenoviral vector expressing the E. coli cytosine deaminase gene and systemic administration of 5-fluorocytosine suppresses growth of hepatic metastasis of colon carcinoma. Gene Therapy 1998; 5: 507-513.
9. Wolff G et al. Ex vivo breast cancer cell purging by adenovirus-mediated cytosine deaminase gene transfer and short-term incubation with 5-fluorocytosine completely prevents tumor growth after transplantation. Hum Gene Ther 1998; 9: 2277-2284.
10. Pederson LC et al. Molecular chemotherapy combined with radiation therapy enhances killing of cholangiocarcinoma cells in vitro and in vivo. Cancer Res 1997; 57: 4325-4332.
11. Freeman SM, Ramesh R, Marrogi AJ. Immune system in suicide-gene therapy. Lancet 1997; 349: 2-3.
12. Cao X et al. Adenovirus-mediated GM-CSF gene and cytosine deaminase gene transfer followed by 5-fluorocytosine administration elicit more potent antitumor tesponse in tumor-bearing mice. Gene Therapy 1998; 5: 1130-1136.
13. Cao X et al. Lymphotactin gene-modified bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity. J Immunol 1998; 161: 6238-6244.
14. Ju DW, Wang B, Cao X. Combined suicide gene and interleukin 2 gene therapy for the treatment of established tumor and induction of antitumor immunity in leukemia-bearing mice. J Cancer Res din Oncol 1998; 124: 683-689.
15. Ju DW, Cao X, Acres B. Intratumoral injection of GM-CSF gene encoded recombinant vaccinia virus elicits potent antitumor response in a murine melanoma model. Cancer Gene Ther 1997; 4: 139-144.
16. Cheon J et al. Chemogene therapy: osteocalcin promoter-based suicide gene therapy in combination with methotrexate in a murine osteosarcoma model. Cancer Gene Ther 1997; 4: 359-365.
17. Fioretti F et al. Reduced tumorigenicity and augmented leukocyte infiltration after monocyte chemotactic protein-3 (MCP-3) gene transfer: perivascular accumulation of dendritic cells in peritumoral tissue and neutrophil recruitment within the tumor. J Immunol 1998; 161: 342-346.
18. Bottazzi B et al. Monocyte chemotactic cytokine gene transfer modulates macrophage infiltration, growth, and susceptibility to IL-2 therapy of a murine melanoma. J Immunol 1992; 148: 1280-1285.
19. Nakashima E et al. A candidate for cancer gene therapy: MIP-1 alpha gene transfer to an adenocarcinoma cell line reduced tumorigenidty and induced protective immunity in immuno-competent mice. Pharm Res 1996; 13: 1896-1901.
20. Kelner GS et al. Lymphotactin: a cytokine that represents a new class of chemokine. Science 1994; 226: 1395-1399.
21. Hedrick JA et al. Lymphotactin is produced by NK cells and attracts both NK cells and T cells in vivo. J Immunol 1997; 158: 1533-1540.
22. Hedrick JA, Zlotnik A. Lymphotactin. Clin Immunol Immunopathol 1998; 87: 218-222.
23. Hedrick JA, Zlotnik A. Lymphotactin: a new class of chemokine. Meth Enzymol 1997; 287: 206-215.
24. Giancarlo B et al. Migratory response of human natural killer cells to lymphotactin. Eur J Immunol 1996; 26: 3238-4241.
25. Aghi M et al. Synergistic anticancer effects of ganciclovir/ thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies. J Natl Cancer Inst 1998; 90: 370-380.
26. Hanna NN et al. Virally directed cytosine deaminase/5-fluorocytosine gene therapy enhances radiation response in human cancer xenografts. Cancer Res 1997; 57: 4205-4209.
27. Freytag SO et al. A novel three-pronged approach to kill cancer cells selectively: concomitant viral, doule suicide gene, and radiotherapy. Hum Gene Ther 1998; 9: 1323-1333.
28. Rogulski KR, Kim JH, Kim SH, Freytag SO. Glioma cells transduced with an Escherichia coli CD/HSV 1 TK fusion gene exhibit enhanced metabolic suicide and radiosensitivity. Hum Gene Ther 1997; 8: 73-85.
29. Kwong YL et al. Combination therapy with suicide and cytokine genes for hepatic metastases of lung cancer. Chest 1997; 112: 1332-1337.
30. Santodonato L et al. Cure of mice with established metastatic friend leukemia cell tumors by a combined therapy with tumor cells expressing both interferon-α1 and herpes simplex thymidine kinase followed by ganciclovir. Gene Therapy 1996; 7: 1-10.
31. Nanni P et al. The immune response elicited by mammary adenocarcinoma cells transduced with interferon-γ and cytosine deaminase genes cures lung metastases by parental cells. Hum Gene Ther 1998; 9: 217-224.
32. Yoon SJ et al. Synergistic antitumor effects with co-expression of GM-CSF and IFN-γ in murine tumors. Int J Cancer 1998; 77: 907-912.
33. Benedetti S et al. Limited efficacy of the HSV-TK/GCV system for gene therapy of malignant gliomas and perspectives for the combined transduction of the interleukin-4 gene. Hum Gene Ther 1997; 8: 1345-1353.
34. Mule JJ et al. RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: role of immune cell subpopulations. Hum Gene Ther 1996; 7: 1545-1553.
35. Nakashima E et al. Synergistic antitumor interaction of human monocyte chemotactant protein-1 gene transfer and modulator for tumor-infiltrating macrophages. Pharm Res 1998; 15: 685-689.
36. Wang J et al. Lymphotactin: a key regulator of lymphocyte trafficking during acute graft rejection. Immunology 1998; 95: 56-61.
37. Dilloo D et al. Combined chemokine and cytokine gene transfer enhances antitumor immunity. Nature Med 1996; 2: 1090-1095.
38. Bi W et al. An HSVtk-mediated local and distant antitumor bystander effect in tumors of head and neck origin in athymic mice. Cancer Gene Ther 1997; 4: 246-252.
39. Denning C, Pitts JD. Bystander effects of different enzyme-prodrug systems for cancer gene therapy depend on different pathways for intercellular transfer of toxic metabolites, a factor that will govern clinical choice of appropriate regimes. Hum Gene Ther 1997; 8: 1825-1835.
40. Chong H et al. Tumour cell expression of B7 costimulatory molecules and interleukin-12 or granulocyte-macrophage colonystimulating factor induces a local antitumour response and may generate systemic protective immunity. Gene Therapy 1998; 5: 223-232.
41. Uzendoski K et al. Construction and characterization of a recombinant vaccinia virus expressing murine intercellular adhesion molecule-1: induction and potentiation of antitumor responses. Hum Gene Ther 1997; 8: 851-860.
42. Ramesh R et al. Expression of costimulatory molecules: B7 and ICAM up-regulation after treatment with a suicide gene. Cancer Gene Ther 1996; 3: 373-384.
43. Hall SJ, Sanford MA, Atkinson G, Chen SH. Induction of potent antitumor natural killer activity by herpes simplex virus-thymidine kinase and ganciclovir therapy in an mouse model of prostate cancer. Cancer Res 1998; 58: 3221-3225.
44. Kanai F et al. In vivo gene therapy for alpha fetoprotein producing hepatocellular carcinoma by adenovirus mediated transfer of cytosine deaminase gene. Cancer Res 1997; 57: 461-465.
45. + T lymphocytes in the primary and memory response of nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene. J Immunol 1992; 149: 3627-3635.
46. Consalvo M et al. 5-Fluorocytosine induced eradication of murine adenocarcinomas engineered to express the cytosine deaminase suicide gene requires host immune competence and leaves an efficient memory. J Immunol 1995; 154: 5302-5312.
47. Toda M, Martuza RL, Kojima H, Rabkin SD. In situ cancer vaccination, an IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity. J Immunol 1998; 160: 4457-4464.